NCT03832179 Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification Status COMPLETED Phase PHASE4
NCT03829410 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Status COMPLETED Phase PHASE1/PHASE2
NCT03818061 Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck Status COMPLETED Phase PHASE2
NCT03813394 Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03806049 Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer Status WITHDRAWN Phase PHASE3
NCT03798626 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Status COMPLETED Phase PHASE1
NCT03792074 To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer Status UNKNOWN Phase PHASE3
NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT03779191 Alectinib in Combination With Bevacizumab in ALK Positive NSCLC Status COMPLETED Phase PHASE2
NCT03778957 A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03762018 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Status COMPLETED Phase PHASE3
NCT03746041 A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes Status COMPLETED Phase PHASE1
NCT03743662 Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Status COMPLETED Phase PHASE3
NCT03737643 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03721653 FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients Status COMPLETED Phase PHASE2
NCT03715933 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Status RECRUITING Phase PHASE1
NCT03713944 Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT03711240 The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases Status UNKNOWN Phase PHASE2